Evidence map›Paper›PMID 38162485›Full record

ArticleFrontiers in oncology2023

TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma.

Sanni Tuominen, Linda Nissi, Antti Kukkula, Johannes Routila, Teemu Huusko, Ilmo Leivo, Heikki Minn, Heikki Irjala, Eliisa Löyttyniemi, Sami Ventelä and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sanni TuominenPreclinical Imaging Laboratory, Turku PET Centre, University of Turku, Turku, Finland.
Linda NissiDepartment of Clinical Oncology, Turku University Hospital and University of Turku, Turku, Finland.
Antti KukkulaCancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.
Johannes RoutilaDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Teemu HuuskoDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Ilmo LeivoDepartment of Pathology, Turku University Hospital and University of Turku, Turku, Finland.
Heikki MinnDepartment of Clinical Oncology, Turku University Hospital and University of Turku, Turku, Finland.
Heikki IrjalaDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Eliisa LöyttyniemiDepartment of Biostatistics, Turku University Hospital and University of Turku, Turku, Finland.
Sami VenteläDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Maria Sundvall *Cancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.
Tove J Grönroos *Preclinical Imaging Laboratory, Turku PET Centre, University of Turku, Turku, Finland.
University of Turku · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Treatment resistance and relapse are common problems in head and neck squamous cell carcinoma (HNSCC). Except for p16, no clinically accepted prognostic biomarkers are available for HNSCC. New biomarkers predictive of recurrence and survival are crucial for optimal treatment planning and patient outcome. High translocator protein (TSPO) levels have been associated with poor survival in cancer, but the role of TSPO has not been extensively evaluated in HNSCC. Materials and methods: TSPO expression was determined in a large population-based tissue microarray cohort including 611 patients with HNSCC and evaluated for survival in several clinicopathological subgroups. A TCGA HNSCC cohort was used to further analyze the role of Results: TSPO expression was downregulated in more aggressive tumors. Low TSPO expression associated with worse 5-year survival and was an independent prognostic factor for disease-specific survival. Subgroup analyses showed that low TSPO expression associated with worse survival particularly in p16-positive oropharyngeal cancer. Conclusion: Decreased TSPO expression associates with poor prognosis in HNSCC. TSPO is a prognostic biomarker in HNSCC to potentially guide treatment stratification especially in p16-positive oropharyngeal cancer.

Indexed as

biomarkerhead and neck cancerimmune landscapeoxidative phosphorylationp16translocator protein

Identifiers

PMID38162485
PMCPMC10755888
OpenAlexW4389727899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.